XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB – Get Free Report) shares passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $2.56 and traded as high as $2.79. XTL Biopharmaceuticals shares last traded at $2.6650, with a volume of 5,791 shares.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a research note on Thursday, April 2nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.
Check Out Our Latest Stock Analysis on XTLB
XTL Biopharmaceuticals Stock Down 4.5%
XTL Biopharmaceuticals Company Profile
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
Read More
- Five stocks we like better than XTL Biopharmaceuticals
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
